Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:ASRT NYSE:DNA NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.71-7.2%$3.07$2.56▼$7.73$567.86M0.212.62 million shs3.12 million shsASRTAssertio$23.440.0%$20.71$8.61▼$23.47$151.54M0.52292,544 shs517,172 shsDNAGinkgo Bioworks$8.17-9.8%$7.93$5.37▼$17.58$591.19M1.791.32 million shs1.52 million shsVALNValneva$5.48-3.4%$5.88$5.06▼$12.25$538M1.7542,327 shs36,900 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.92%-4.89%-4.58%-17.51%-46.81%ASRTAssertio-0.09%+0.04%+5.82%+100.09%+134.52%DNAGinkgo Bioworks+3.67%-4.82%-6.75%+38.51%+19.64%VALNValneva+1.61%-10.00%+7.18%-46.10%-9.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.71-7.2%$3.07$2.56▼$7.73$567.86M0.212.62 million shs3.12 million shsASRTAssertio$23.440.0%$20.71$8.61▼$23.47$151.54M0.52292,544 shs517,172 shsDNAGinkgo Bioworks$8.17-9.8%$7.93$5.37▼$17.58$591.19M1.791.32 million shs1.52 million shsVALNValneva$5.48-3.4%$5.88$5.06▼$12.25$538M1.7542,327 shs36,900 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.92%-4.89%-4.58%-17.51%-46.81%ASRTAssertio-0.09%+0.04%+5.82%+100.09%+134.52%DNAGinkgo Bioworks+3.67%-4.82%-6.75%+38.51%+19.64%VALNValneva+1.61%-10.00%+7.18%-46.10%-9.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$16.67515.01% UpsideASRTAssertio 1.80Reduce$22.65-3.37% DownsideDNAGinkgo Bioworks 1.67Reduce$8.504.10% UpsideVALNValneva 2.20Hold$11.98118.52% UpsideCurrent Analyst Ratings BreakdownLatest ASRT, DNA, ALT, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.005/13/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$21.80 ➝ $23.505/5/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $21.804/22/2026VALNValneva The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$4.904/20/2026ASRTAssertio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DNAGinkgo Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026VALNValneva GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.004/9/2026ASRTAssertio Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/9/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$45.00 ➝ $18.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$36K14,639.57N/AN/A$1.99 per share1.36ASRTAssertio$102.16M1.48$0.02 per share1,435.45$14.63 per share1.60DNAGinkgo Bioworks$151.40M3.52N/AN/A$8.74 per share0.93VALNValneva$197.56M2.63N/AN/A$1.39 per share3.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)ASRTAssertio-$30.38M-$5.69N/A21.12N/A-34.94%-38.72%-13.32%7/30/2026 (Estimated)DNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)VALNValneva-$130.33M-$1.87N/A2.90N/A-88.87%-107.63%-33.02%8/11/2026 (Estimated)Latest ASRT, DNA, ALT, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/13/2026Q1 2026VALNValneva-$0.1485-$0.42-$0.2715-$0.42$54.69 million$36.16 million5/8/2026Q1 2026ASRTAssertio-$2.1025-$2.93-$0.8275-$2.93$8.97 million$9.93 million3/31/2026Q4 2025VALNValnevaN/A-$0.42N/A-$0.42N/A$35.77 million3/16/2026Q4 2025ASRTAssertio-$3.05-$1.86+$1.19-$1.86$6.20 million$13.54 million3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AASRTAssertioN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56ASRTAssertio0.521.821.57DNAGinkgo BioworksN/A5.155.15VALNValneva2.142.141.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%ASRTAssertio48.96%DNAGinkgo Bioworks78.63%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%ASRTAssertio5.70%DNAGinkgo Bioworks12.69%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableASRTAssertio206.46 million6.09 millionOptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionableVALNValneva70094.89 million80.74 millionNot OptionableASRT, DNA, ALT, and VALN HeadlinesRecent News About These CompaniesValneva Announces Availability of Documentation for its Annual General MeetingJune 4 at 1:00 AM | globenewswire.comVALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026June 3 at 8:14 PM | finance.yahoo.comValneva (NASDAQ:VALN) Raised to Sell at Wall Street ZenJune 1, 2026 | americanbankingnews.comValneva annonce sa participation à des conférences investisseurs aux États-Unis et en EuropeMay 28, 2026 | globenewswire.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 28, 2026 | globenewswire.comValneva SE 2026 Q1 - Results - Earnings Call PresentationMay 16, 2026 | seekingalpha.comValneva SE (VALN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comValneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...May 13, 2026 | uk.finance.yahoo.comValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccinesMay 13, 2026 | fiercebiotech.comFValneva Q1 Earnings Call HighlightsMay 13, 2026 | marketbeat.comValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNMay 7, 2026 | prnewswire.comVALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026May 5, 2026 | globenewswire.comValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026May 5, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 30, 2026 | prnewswire.comValneva Announces the Successful Completion of an €84 million Reserved OfferingApril 30, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 28, 2026 | globenewswire.comAs tick season drags longer, Pfizer hopes to release a Lyme disease vaccine in 2027April 27, 2026 | politifact.comPValneva's Commercial Crossroads: A Vaccine Maker's Pivotal YearApril 23, 2026 | aktiencheck.deAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNApril 21, 2026 | globenewswire.comA vaccine for Lyme disease could be on the horizonApril 20, 2026 | sciencenews.orgSNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming DueBy Bridget Bennett | May 9, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026Palantir and Dell Build an AI OS for the ParanoidBy Chris Markoch | May 24, 2026ASRT, DNA, ALT, and VALN Company DescriptionsAltimmune NASDAQ:ALT$2.71 -0.21 (-7.19%) Closing price 04:00 PM EasternExtended Trading$2.70 0.00 (-0.18%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Assertio NASDAQ:ASRT$23.44 -0.01 (-0.04%) Closing price 04:00 PM EasternExtended Trading$23.44 0.00 (-0.01%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Ginkgo Bioworks NYSE:DNA$8.16 -0.89 (-9.78%) Closing price 03:59 PM EasternExtended Trading$8.14 -0.03 (-0.37%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Valneva NASDAQ:VALN$5.48 -0.19 (-3.35%) Closing price 04:00 PM EasternExtended Trading$5.44 -0.04 (-0.64%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
